GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hisamitsu Pharmaceutical Co Inc (TSE:4530) » Definitions » Cash Flow from Financing

Hisamitsu Pharmaceutical Co (TSE:4530) Cash Flow from Financing : 円0 Mil (TTM As of Nov. 2023)


View and export this data going back to 1962. Start your Free Trial

What is Hisamitsu Pharmaceutical Co Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Nov. 2023, Hisamitsu Pharmaceutical Co paid 円0 Mil more to buy back shares than it received from issuing new shares. It received 円0 Mil from issuing more debt. It paid 円0 Mil more to buy back preferred shares than it received from issuing preferred shares. It received 円0 Mil from paying cash dividends to shareholders. It received 円0 Mil on other financial activities. In all, Hisamitsu Pharmaceutical Co spent 円0 Mil on financial activities for the three months ended in Nov. 2023.


Hisamitsu Pharmaceutical Co Cash Flow from Financing Historical Data

The historical data trend for Hisamitsu Pharmaceutical Co's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hisamitsu Pharmaceutical Co Cash Flow from Financing Chart

Hisamitsu Pharmaceutical Co Annual Data
Trend Feb15 Feb16 Feb17 Feb18 Feb19 Feb20 Feb21 Feb22 Feb23 Feb24
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -11,726.00 -7,187.00 -15,189.00 -14,687.00 -16,691.00

Hisamitsu Pharmaceutical Co Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Hisamitsu Pharmaceutical Co Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Hisamitsu Pharmaceutical Co's Cash from Financing for the fiscal year that ended in Feb. 2024 is calculated as:

Hisamitsu Pharmaceutical Co's Cash from Financing for the quarter that ended in Nov. 2023 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Nov. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hisamitsu Pharmaceutical Co  (TSE:4530) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Hisamitsu Pharmaceutical Co's issuance of stock for the three months ended in Nov. 2023 was 円0 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Hisamitsu Pharmaceutical Co's repurchase of stock for the three months ended in Nov. 2023 was 円0 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Hisamitsu Pharmaceutical Co's net issuance of debt for the three months ended in Nov. 2023 was 円0 Mil. Hisamitsu Pharmaceutical Co received 円0 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Hisamitsu Pharmaceutical Co's net issuance of preferred for the three months ended in Nov. 2023 was 円0 Mil. Hisamitsu Pharmaceutical Co paid 円0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Hisamitsu Pharmaceutical Co's cash flow for dividends for the three months ended in Nov. 2023 was 円0 Mil. Hisamitsu Pharmaceutical Co received 円0 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Hisamitsu Pharmaceutical Co's other financing for the three months ended in Nov. 2023 was 円0 Mil. Hisamitsu Pharmaceutical Co received 円0 Mil on other financial activities.


Hisamitsu Pharmaceutical Co Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Hisamitsu Pharmaceutical Co's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Hisamitsu Pharmaceutical Co (TSE:4530) Business Description

Traded in Other Exchanges
Address
408 Tashiro Daikan-machi, Tosu, Saga, JPN, 841-0017
Hisamitsu Pharmaceutical Co Inc is a major pharmaceutical products manufacturer in Japan. The company collaborates with its subsidiaries and associates in operating its business across two segments, The Medical and Related Product segment and the Others segment. The Medical segment represents the company's foremost revenue generating operations. It markets drugs under the Salanpas, Salonsip, Lifecella, Mohrus and Keplat brands, which mainly serve topical medication needs with pain relief creams, gels, sprays, lotions and ointments. The Others segment refers to its miscellaneous businesses such as cable television broadcasting, internet connection, packing materials and insurance. Apart from its primary market in Japan, Hisamitsu has a reach across other regions like North America.

Hisamitsu Pharmaceutical Co (TSE:4530) Headlines

No Headlines